Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)-Reference-Cited by-同舟云学术

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

Published:2021-05-31 Issue:6 Volume:14 Page:849-862
ISSN:1178-1653
Container-title:The Patient - Patient-Centered Outcomes Research
language:en
Short-container-title:Patient

Author:

Chounta Vasiliki^ORCID,Overton Edgar T.,Mills Anthony,Swindells Susan,Benn Paul D.,Vanveggel Simon,van Solingen-Ristea Rodica,Wang Yuanyuan,Hudson Krischan J.,Shaefer Mark S.,Margolis David A.,Smith Kimberly Y.,Spreen William R.

Funder

ViiV Healthcare

Janssen

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40271-021-00524-0.pdf

Reference41 articles.

1. Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. PLoSOne. 2014;9:e97482.

2. Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings. Antivir Ther. 2014;19(Suppl 3):31–7.

3. Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine. 2015;94:e1677.

4. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13:e1002183.